Multidisciplinary Management of DMD
Released On
February 6, 2025
Expires On
February 6, 2026
Media Type
Internet
Completion Time
15 minutes
Specialty
Cardiology, Genetics, Neurology, Pediatrics, Primary Care, Pulmonology
Topics
Duchenne Muscular Dystrophy (DMD), Pediatrics
This independent content was supported by an educational grant from Pfizer.
This module is not accredited
Target Audience
This activity is designed to meet the educational needs of pediatric neurologists, primary care physicians, pediatricians, geneticists, genetic counselors, neuromuscular specialists, nurse practitioners, pulmonologists, cardiologists, endocrinologists, orthopedists and physical therapists engaged in the care of patients with Duchenne Muscular Dystrophy (DMD).
Program Overview
This activity will cover the best practices for the multidisciplinary management of Duchenne Muscular Dystrophy (DMD), including the standard of care for DMD patients and how to manage the various clinical manifestations of the disease.
Learning Objectives
After participating in this program, you will be able to:
- Describe the established standard of care for patients diagnosed with DMD
- Explain multidisciplinary team approaches, including potential challenges, for optimizing patient management and improving quality of life
- Discuss recommendations to refine DMD treatment strategies, continuity of care, and patient monitoring
Faculty
Nadia Merchant
Assistant Professor of Pediatrics, Pediatric Endocrinology and Medical Genetics, Children's Health/University of Texas Southwestern, Texas, USA
Nadia Merchant, M.D., is a pediatric endocrinologist and geneticist at Children’s Health/University of Texas Southwestern in Dallas, Texas. Dr. Merchant’s clinical interests include bone health and the intersection of genetics and endocrinology, especially bone health, calcium disorders, neuromuscular disorders and skeletal dysplasias. She is passionate about maximizing a patient’s potential.
Laurent Servais
Professor of paediatrics neuromuscular diseases at the University of Oxford and part-time Professor at the University of Liege, Belgium
Laurent Servais, MD, PhD is professor of paediatrics neuromuscular diseases at the University of Oxford and part-time Professor at the University of Liege, Belgium. He graduated from the University of Louvain (Medicine) and Brussels (Paediatrics), and trained as a child neurologist in Robert Debré Hospital (Paris) and as a myologist in the Institute of Myology, in La Pitié Salpétrière (Paris). His main research interests cover innovative outcome measures and clinical trials design and newborn screening. He has been involved as PI in several clinical trials in spinal muscular atrophy, X-Myotubular Myopathy and Duchenne Muscular Dystrophy, and in leading the pioneering newborn screening program for spinal muscular atrophy newborn screening in Belgium.
Disclosures of Conflicts of Interest
Nadia Merchant
Honoraria or consultation fees: Pfizer and BioMarin for Growth Advisory Board
Laurent Servais
Grants/research support: Roche, Biogen, Novartis, Sysnav, Zentech, Scholar Rock, BioHaven
Honoraria or consultation fees: Roche, Biogen-Novartis, Sysnav, Zentech, Scholar Rock, BioHaven, Pfizer, Sarepta, Dyne, Astellas, Cerebral Therapeutics, Illumina, Altana, Solid, Regenex Bio, Santhera, Italfarmaco
Instructions for Participation and Credit
There are no fees for participating in this enduring activity.
Disclosure of Unlabeled Use
Faculty participating in any CME activity are required to disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Contact Information
For questions, please contact: [email protected].